Purpose: To evaluate the anatomical and functional results after ocriplasmin (JETREA, ThromboGenics NV, Iselin, NJ, USA) injection in patients with vitreomacular traction (VMT) with or without macular hole (MH). Methods: Fifteen prospective patients with VMT were treated with a single ocriplasmin injection and followed-up at baseline, 1 week, 1, 3 and 6 months. ETDRS best-corrected visual acuity (BCVA), intraocular pressure and...
Read MoreClinical Experience of Ocriplasmin for Vitreomacular Traction and MH
Posted by Fernando Faus, Pilar Calvo, Sonia Fernandez, Antonio Ferreras, Arturo Rodriguez, Jorge Sierra, Beatriz Abadia, Fernando Gutierrez and Emilio Abecia Martinez on Apr 28, 2016 in Intravitreal injection, Vitreomacular traction